Potent synthetic ghrelin/GHSR-1a receptor agonist
PRODUCT PROFILE
Hexarelin
£51.00
Hexarelin is potent synthetic ghrelin/ghsr-1a receptor agonist. Researchers examine it in relation to acute gh release and broader pituitary-hormone responses.
Why it is distinct
A potent older GHRP with less hormonal selectivity than ipamorelin.
- Evidence stageEarly human evidence
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Hexarelin is potent synthetic ghrelin/ghsr-1a receptor agonist. Researchers examine it in relation to acute gh release and broader pituitary-hormone responses.
Research focus+
Researchers study how it activates the ghrelin receptor and affects growth-hormone release, including effects on other pituitary signals. Human evidence is limited and it is not an authorised medicine.
How the mechanism differs+
Activates the ghrelin receptor; human challenge studies also observed prolactin, cortisol and ACTH responses.
Evidence and limitations+
Small controlled human pharmacology studies demonstrate GH release, but therapeutic outcome and long-term safety data are limited.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study how it activates the ghrelin receptor and affects growth-hormone release, including effects on other pituitary signals. Human evidence is limited and it is not an authorised medicine.
Activates the ghrelin receptor; human challenge studies also observed prolactin, cortisol and ACTH responses.
A potent older GHRP with less hormonal selectivity than ipamorelin.
Small controlled human pharmacology studies demonstrate GH release, but therapeutic outcome and long-term safety data are limited.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
GHRP-2
£44.005 mgBatch file pendingTypically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
UnavailableAsk about availability